Indication
CD55-deficient protein-losing enteropathy
1 clinical trial
1 product
Product
PozelimabClinical trial
An Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)Status: Active (not recruiting), Estimated PCD: 2021-11-09